COVID-19 - A set of symptoms or a systemic pathology? Clinical lecture Part 2. Areplivir (favipiravir) in the treatment of patients with coronavirus infection: Background of use and first results

ABSTRACT

Clinical practice shows that in addition to a life-threatening condition caused by lung damage, the SARS-CoV-2 virus provokes multiple organ damage and systemic endothelial inflammation, leading to serious, often fatal consequences. The complex pathophysiology of the virus and the mechanisms of its effect on the body require the development of complex therapy aimed at minimizing the systemic damage, as well as protecting the organs and tissues involved in order to improve the prognosis of the course of the disease. Early initiation of antiviral therapy aimed at inhibiting a specific mechanism of the SARS-CoV-2 virus is necessary to reduce the viral load and the risk of complications. The review provides information on the safety and clinical efficacy of favipiravir in the treatment of infectious diseases caused by RNA viruses, in particular COVID-19, as well as the possibility of using Areplivir (favipiravir) in patients with new coronavirus infection. © 2021 Nutritec. All rights reserved.